Actively Recruiting
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Led by IHU Strasbourg · Updated on 2026-04-16
60
Participants Needed
2
Research Sites
105 weeks
Total Duration
On this page
Sponsors
I
IHU Strasbourg
Lead Sponsor
L
Luxembourg Institute of Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of all digestive cancers due to lack of early diagnosis and limited response to treatment. Patient-derived organoid technology has become a mainstay of precision oncology, enabling personalised functional characterisation of tumours (e.g. treatment evaluation and drug screening). Initial research carried out as part of the Cancer Profile project has produced the first organoids from resected PDAC parts. Only 15-20% of patients can benefit from surgical resection, which remains the only curative treatment. In contrast, most patients with PDAC undergo diagnostic fine-needle biopsies (FNB) using an echo-endoscopic procedure (EUS). The next step is therefore the reliable generation of organoids from limited quantities of biopsy material obtained by 'EUS-FNB'. The aim of the study presented here is to validate these organoids on the basis of the following characteristics: (i) morphological and proliferative characteristics, (ii) recapitulation of the genetic characteristics of the original tumour, (iii) expression of tumour markers.
CONDITIONS
Official Title
Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient over 18 years of age.
- Patient undergoing echo-endoscopy with certainty or suspicion of fine needle biopsy (EUS-FNB).
- Suspicion of pancreatic lesion.
- Patient able to receive and understand information about the research and provide consent.
- Patient affiliated with the French social security system.
You will not qualify if you...
- Patient not scheduled for endoscopy with certainty or suspicion of fine needle biopsy (EUS-FNB).
- Patient undergoing echo-endoscopy with high risk that may prevent EUS-FNB.
- Patient with degenerated Intraductal papillary mucinous neoplasm (IPMN).
- Patient with acute pancreatitis within 4 weeks prior to EUS.
- Pregnant or breastfeeding patient.
- Patient under court protection.
- Patient under guardianship or curatorship.
- Patient in a situation of social vulnerability.
- Patient under legal protection or unable to express opposition.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Centre d'Endoscopie Digestive
Strasbourg, France
Actively Recruiting
2
Department of hepato-gastroenterology
Strasbourg, France
Actively Recruiting
Research Team
A
Armelle TAKEDA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here